ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to Sell by ValuEngine

ValuEngine upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a strong sell rating to a sell rating in a report released on Tuesday morning, ValuEngine reports.

Several other equities analysts have also recently weighed in on ANIP. BidaskClub raised shares of ANI Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, October 22nd. Raymond James dropped their price target on shares of ANI Pharmaceuticals from $82.00 to $75.00 and set an outperform rating on the stock in a research report on Thursday, November 7th. Guggenheim assumed coverage on shares of ANI Pharmaceuticals in a research note on Thursday, September 12th. They issued a buy rating and a $76.00 price target for the company. Finally, Zacks Investment Research downgraded shares of ANI Pharmaceuticals from a hold rating to a strong sell rating in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company. ANI Pharmaceuticals has an average rating of Hold and an average target price of $85.00.

Shares of NASDAQ ANIP traded up $0.50 during mid-day trading on Tuesday, hitting $57.06. The company had a trading volume of 109,669 shares, compared to its average volume of 138,567. The company has a market capitalization of $673.90 million, a PE ratio of 12.37 and a beta of 2.20. The firm has a 50-day simple moving average of $70.51 and a two-hundred day simple moving average of $72.90. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.30. ANI Pharmaceuticals has a one year low of $36.92 and a one year high of $86.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.20). The company had revenue of $51.30 million for the quarter, compared to the consensus estimate of $56.10 million. ANI Pharmaceuticals had a return on equity of 28.28% and a net margin of 7.58%. The business’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.29 EPS. Sell-side analysts expect that ANI Pharmaceuticals will post 4.58 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Mason Street Advisors LLC raised its position in shares of ANI Pharmaceuticals by 12.2% in the third quarter. Mason Street Advisors LLC now owns 3,157 shares of the specialty pharmaceutical company’s stock valued at $230,000 after purchasing an additional 344 shares during the period. Monarch Partners Asset Management LLC grew its holdings in ANI Pharmaceuticals by 13.4% in the 3rd quarter. Monarch Partners Asset Management LLC now owns 4,910 shares of the specialty pharmaceutical company’s stock valued at $358,000 after buying an additional 580 shares in the last quarter. SG Americas Securities LLC grew its holdings in ANI Pharmaceuticals by 248.2% in the 3rd quarter. SG Americas Securities LLC now owns 30,544 shares of the specialty pharmaceutical company’s stock valued at $2,226,000 after buying an additional 21,773 shares in the last quarter. Yorktown Management & Research Co Inc acquired a new position in ANI Pharmaceuticals in the 3rd quarter valued at $295,000. Finally, Russell Investments Group Ltd. bought a new position in ANI Pharmaceuticals during the 3rd quarter worth $7,028,000. Institutional investors own 72.28% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Recommended Story: Capital Gains

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.